Nasdaq
$11.26▲ 0.72%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.52BShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 8.10Regular26.08.11 02:26144Ownership#●●●#●●●
COMPASS Pathways plcBullish
COMPASS Pathways plc의 내부자 Annalisa Jenkins가 SEC Form 144를 통해 자사주 매도를 신고했습니다. 이는 경영진의 보유 지분 처분 계획을 공식화한 것으로, 향후 해당 물량의 시장 출회 가능성을 의미합니다.…more
$11.26+0.72%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.7Regular26.08.08 00:35144Ownership
COMPASS Pathways plc
COMPASS Pathways plc의 이사인 Annalisa Jenkins가 보유 주식에 대한 매도 계획을 담은 Form 144를 제출했습니다. 이는 내부자의 지분 매도 의사를 공식화한 것으로, 향후 해당 물량이 시장에 출회될 예정입니다.…more
$11.26+0.72%vs prev closeView filingShare - 8.5After-hours26.08.06 05:184Ownership
COMPASS Pathways plc
COMPASS Pathways plc의 내부자인 Nath Kabir가 2026년 8월 3일자로 주식 관련 거래를 수행하여 SEC Form 4를 통해 보고하였습니다. 해당 공시는 내부자의 지분 변동 사항을 공식적으로 기록한 것입니다.…more
$11.26+0.72%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.10Pre-market26.09.10 19:41#●●●#●●●
Compass Pathways Announces Grant Recipients for Psychedelic Treatment Training…more
Compass Pathways has selected five organizations to receive grants for developing training programs for its potential psychedelic treatment, COMP360. This initiative aims to ensure healthcare providers are prepared for patient care following the treatment's expected commercial launch.…more
$11.26+0.72%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9Regular26.09.10 02:18
●●●●●●●● ●●●●● ●●●●●●
Compass Pathways announced that its COMP360 psilocybin therapy demonstrated durable long-term benefits in a Phase 3 study for treatment-resistant depression. The company is on track to complete its New Drug Application filing this year, targeting a commercial launch in early 2027.…more
$11.26+0.72%vs prev closeShareBenzinga - 9.9Pre-market26.09.09 19:37
●●●●●●●● ●●●●● ●●●●●●
Compass Pathways announced that its Phase 3 trial for the treatment-resistant depression drug COMP360 demonstrated durable therapeutic benefits lasting up to one year. The company remains on track to complete its NDA submission in the fourth quarter, targeting a commercial launch in the first half of 2027.…more
$11.26+0.72%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report